Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2021-07-19 M&A Activity
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
PRTC’s Gelesis to Become Public Via Capstar SPAC
M&A Activity Classification · 99% confidence The document is an RNS (Regulatory News Service) announcement from PureTech Health PLC, dated July 19, 2021. The core content announces that PureTech's Founded Entity, Gelesis, is merging with a Special Purpose Acquisition Company (Capstar) to become publicly traded. This type of announcement—a significant corporate action involving a merger/acquisition (M&A) and subsequent listing—is typically disseminated via regulatory news wires. Although it details a transaction that will eventually lead to a Form 8-K filing (mentioned at the end), the immediate format and distribution method (RNS Number: 6869F) strongly indicate a general regulatory announcement. Since the document is an announcement of a major corporate event (a SPAC merger/takeover bid structure) and is distributed via RNS, the most appropriate classification is 'Regulatory Filings' (RNS) as a general disclosure, or potentially 'M&A Activity' (TAR). Given the structure is a definitive business combination agreement announcement via RNS, RNS is a strong fit, but TAR specifically covers merger proposals. Since the document explicitly details the merger agreement, transaction overview, and advisors, TAR (M&A Activity) is more specific than the general RNS fallback. However, the document is clearly distributed as an RNS release. Reviewing the definitions, TAR covers 'merger proposals or takeover bids.' This is a definitive agreement for a merger. I will classify it as TAR due to the specific subject matter, but acknowledge its RNS distribution format.
2021-07-19 English
PRTC’s Vor Announces Collaboration with Janssen
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and is dated '09 July 2021'. It reports on an announcement made by PureTech Health plc regarding its Founded Entity, Vor Biopharma, entering a collaboration with Janssen. The text explicitly states, 'This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' and later, 'Reach announcements are identified with an orange label... so that they are distinguished from the RNS UK regulatory service.' Since this is a press release distributed via the RNS system but explicitly marked as non-regulatory news (Reach), and it does not fit the specific definitions for ER, CT, DIV, etc., the most appropriate general category for a miscellaneous, non-core regulatory announcement distributed through this channel is 'Regulatory Filings' (RNS), which serves as the fallback for such announcements that are not otherwise classified, even if they are explicitly non-regulatory news releases.
2021-07-09 English
PRTC’s Sonde Announces Collaboration With Qualcomm
Regulatory Filings Classification · 99% confidence The document is identified by the RNS Number header and contains a date (08 July 2021). The content is an announcement from PureTech Health plc noting a collaboration between its Founded Entity, Sonde Health, and Qualcomm Technologies regarding vocal biomarker technology. The footer explicitly states, "This information is provided by Reach, the non-regulatory press release distribution service of RNS... Reach announcements are identified with an orange label...". This structure strongly indicates a general regulatory or press announcement that is distributed via the RNS system but is explicitly marked as non-regulatory news (Reach). Since it is not a specific financial report (like 10-K, IR, ER) or a specific corporate action (like DIV, DIRS, CAP), the most appropriate fallback category for a general, non-regulatory press release distributed through the RNS mechanism is 'Regulatory Filings' (RNS), as it serves as the general announcement channel.
2021-07-08 English
PRTC BeiGene LYT-200 Clinical Trial Agreement
Legal Proceedings Report Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory or news service announcement. The content describes a clinical trial and supply agreement between PureTech Health and BeiGene regarding a drug candidate (LYT-200) and mentions expected topline results in Q4 2021. This is a corporate development announcement concerning partnerships and clinical progress, not a full financial report (like 10-K or IR) or a transcript. Since it is a specific corporate announcement distributed via the RNS system, and it details a significant business development (collaboration/licensing), it fits best under the general 'Regulatory Filings' category (RNS) as a broad announcement, although it shares characteristics with other updates. Given the options, and since it is a formal announcement distributed through the RNS mechanism detailing business operations/agreements, RNS is the most appropriate general classification if a more specific one like 'TAR' (M&A Activity) doesn't strictly apply (this is a clinical supply agreement, not a takeover). However, looking closely at the definitions, this is a press release announcing a significant business event (a clinical trial agreement). Since there is no specific code for 'Clinical Trial Update' or 'Partnership Announcement', and it is clearly distributed via RNS, the fallback 'RNS' is appropriate, or potentially 'LTR' if it were a legal proceeding, which it is not. Given the structure and distribution method (RNS Number, press release format), RNS is the safest classification for a general, non-financial, non-governance regulatory announcement.
2021-07-07 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly labeled with "RNS Number : 7081D" and contains information regarding the 'Total Voting Rights and Share Capital' as of a specific month-end date (30 June 2021). This type of disclosure, mandated by DTR 5.6.1 (Disclosure Guidance and Transparency Rules), is a routine regulatory announcement distributed via the RNS system of the London Stock Exchange. While it contains specific data, it is not a comprehensive report (like 10-K or IR) nor a specific announcement like a dividend (DIV) or director dealing (DIRS). It fits best under the general regulatory announcement category, RNS, as it is a standard, periodic regulatory update distributed through that channel.
2021-07-01 English
PRTC’s Vedanta Announces New Data from IBD Study
Regulatory Filings Classification · 98% confidence The document begins with an RNS Number and is dated June 30, 2021. It details an announcement made by PureTech Health plc regarding positive clinical trial data for a product developed by its Founded Entity, Vedanta Biosciences. The text is structured as a press release, providing key updates, detailed results, and background information on the science and the companies involved. Crucially, the footer explicitly states: "This information is provided by Reach, the non-regulatory press release distribution service of RNS... Reach announcements are identified with an orange label and the word “Reach" in the source column... Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature." Since this is a press release announcing business/clinical progress that is explicitly marked as non-regulatory and distributed via the RNS system, it fits best under the general Regulatory Filings (RNS) category, which serves as a fallback for non-standard or non-mandated announcements distributed through this channel, rather than a specific financial report like 10-K, ER, or IR.
2021-06-30 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.